Delivering an Enzyme to the Brain: Genentech Licenses Alector’s Parkinson’s Therapy for $100 Million Upfront

Replacing an enzyme that is deficient in the brain requires more than producing it: the enzyme must also cross the blood-brain barrier and reach the cells that need it. Alector announced on October 5 that it had granted Genentech, part of the Roche Group, an exclusive global license to its AL050 program, which is being developed toward this goal. The agreement secures resources for further development of an enzyme replacement therapy targeting Parkinson’s disease and other neurodegenerative diseases.

According to documents Alector filed with the U.S. Securities and Exchange Commission, the companies signed the agreement on September 30. Genentech will pay $100 million upfront; if development, regulatory and commercial milestones are achieved, Alector may receive up to an additional $1.17 billion, along with tiered royalties based on net sales. Reuters also reported the deal. The upfront payment and milestone payments total up to $1.27 billion, but the latter depend on future outcomes and are not revenue available upon signing.

At the core of AL050 is glucocerebrosidase (GCase). According to Alector, insufficient activity of this enzyme is associated with neurodegeneration in Parkinson’s disease, particularly in people with GBA1 gene variants, though the association is not limited to this group. When GCase function is insufficient, lipids such as glucosylsphingosine and glucosylceramide may accumulate in neurons and other brain cells; AL050 aims to improve this metabolic pathway by supplementing the enzyme.

To this end, Alector combines engineered GCase, designed to increase activity and extend its half-life, with its proprietary Alector Brain Carrier (ABC) delivery platform. The former addresses whether the enzyme can act effectively and for a sustained period, while the latter seeks to help it cross the blood-brain barrier. Clearing accumulated lipids, reducing cellular dysfunction and ultimately slowing disease progression are the therapeutic goals of this design; they cannot yet be regarded as effects demonstrated in human patients.

Following the licensing agreement, Genentech will assume responsibility for development, regulatory activities, manufacturing and commercialization across all indications. Alector will retain ownership of the ABC platform and may continue using it in its own research and development programs beyond GCase. This gives the deal significance beyond a single therapeutic candidate: Alector is handing an enzyme development program to a large pharmaceutical company while retaining the ability to apply its delivery technology to other drug candidates.

However, the focus of this announcement remains the licensing agreement. It disclosed no human efficacy or safety results for AL050 and provided no new timeline for initiating clinical trials. Several steps still require validation, from the enzyme entering the brain, to effectively breaking down lipids, to actually slowing disease progression in patients. This collaboration establishes who will undertake the next stage of development; whether it can translate into a therapeutic advance still requires evidence from subsequent studies.